Canada markets close in 4 hours 31 minutes

Mydecine Innovations Group Inc. (MYCOF)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
0.5800-0.1100 (-15.94%)
As of 10:48AM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Previous Close0.6900
Open0.6200
BidN/A x N/A
AskN/A x N/A
Day's Range0.5800 - 0.6200
52 Week Range0.0010 - 2.4500
Volume2,855
Avg. Volume15,948
Market Cap3.115M
Beta (5Y Monthly)3.95
PE Ratio (TTM)N/A
EPS (TTM)-4.6810
Earnings DateMay 16, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est140.00
  • CNW Group

    IIROC Trading Halt - MYCO

    The following issues have been halted by IIROC:

  • GlobeNewswire

    Mydecine Files Full Patent Application Covering MYCO-006 Family of Novel Short-Acting MDMA Analogs

    Company aims to increase health equity by developing more accessible treatment modalities better suited for existing healthcare infrastructureDENVER, July 19, 2022 (GLOBE NEWSWIRE) -- Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) (“Mydecine” or the “Company”), a biotechnology company aiming to transform the treatment of mental health and addiction disorders, announced it has successfully synthesized multiple short-acting MDMA analogs. This family of analogs have been speci

  • GlobeNewswire

    U.S. FDA Clears MYCO-001 for Multi-Site Government Funded Trial in Smoking Cessation

    DENVER, June 17, 2022 (GLOBE NEWSWIRE) -- Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) (“Mydecine” or the “Company”), a biotechnology aiming to transform the treatment of mental health and addiction disorders, today announced that the U.S. Food and Drug Administration (FDA) has cleared MYCO-001 in a recent Investigational New Drug (IND) application, marking the first clearance of the Company’s drug product. The Investigator Initiated trial is funded by a near $4 million grant